MedAssets Reports Second Quarter and Six-Month 2013 Financial Results
MedAssets Reports Second Quarter and Six-Month 2013 Financial Results
ATLANTA--(BUSINESS WIRE)-- MedAssets, Inc. (NAS: MDAS) today announced results for its second quarter and six-month periods ended June 30, 2013. Second quarter results are summarized in the table below:
|($ in millions, except per share)||2Q'13||2Q'12||% Change|
|Spend and Clinical Resource Mgmt (SCM)||$||105.3||$||102.1||3.1||%|
|Revenue Cycle Management (RCM)||65.4||60.9||7.5|
|Total Net Revenue||170.7||163.0||4.7|
|Earnings per share (EPS) - diluted||0.08||0.04||100.0|
|Non-GAAP adjusted EBITDA||52.5||49.0||7.2|
|Non-GAAP adjusted EPS - diluted||$||0.30||$||0.28||7.1|
|Weighted average shares - diluted||60.7||58.7||3.4||%|
Total net revenue for the second quarter of 2013 increased 4.7% to $170.7 million from $163.0 million for the second quarter of 2012. Net revenue in the SCM segment increased 3.1% to $105.3 million from net revenue of $102.1 million for the second quarter of 2012, due primarily to group purchasing net administrative fee growth, partially offset by an expected year-over-year decrease in performance-related fees. Net revenue in the RCM segment increased 7.5% to $65.4 million from $60.9 million for the second quarter of 2012 as technology-related revenue increased 6.5% while services-related revenue grew 9.7%.
Total net revenue for the first half of 2013 increased 9.8% to $343.6 million from $312.9 million for the first half of 2012. Net revenue in the SCM segment grew 9.9% to $214.8 million from net revenue of $195.4 million for the first half of 2012. Net revenue in the RCM segment increased 9.6% to $128.8 million from $117.5 million for the first half of 2012 as technology-related revenue grew 7.3% and services-related revenue increased 14.9%.
Non-GAAP Adjusted EBITDA
Total non-GAAP adjusted EBITDA was $52.5 million, or 30.8% of total net revenue, for the second quarter of 2013, a 7.2% increase from total non-GAAP adjusted EBITDA of $49.0 million, or 30.1% of total net revenue, for the second quarter of 2012. The 71 basis point margin increase was due to higher RCM segment margin and relatively flat corporate expenses, partially offset by an expected year-over-year decrease in performance-related fees.
For the first half of 2013, total non-GAAP adjusted EBITDA was $114.2 million, or 33.2% of total net revenue, a 19.7% increase over total non-GAAP adjusted EBITDA of $95.4 million, or 30.5% of total net revenue, for the first half of 2012.
Net Income and Non-GAAP Adjusted Earnings Per Share (EPS)
The Company reported net income for the second quarter of 2013 of $5.1 million, or $0.08 per share, compared to net income of $2.3 million, or $0.04 per share, for the second quarter of 2012.
Non-GAAP adjusted EPS (defined as EPS excluding non-cash acquisition-related intangible amortization and depreciation, non-cash share-based compensation, certain acquisition and integration-related expenses and non-recurring items on a tax-adjusted basis) was $0.30 per share for the second quarter of 2013, a 7.1% increase when compared with non-GAAP adjusted EPS of $0.28 per share for the second quarter of 2012.
Net income for the first half of 2013 was $12.8 million, or $0.21 per share, versus net income of $2.0 million, or $0.03 per share, for the first half of 2012. Non-GAAP adjusted EPS was $0.71 per share for the first half of 2013, a 39.2% increase over non-GAAP adjusted EPS of $0.51 per share for the first half of 2012.
Cash Flow and Capital Resources
Cash provided by operating activities in the first half of 2013 was $67.6 million versus $62.7 million for the same period of 2012. Non-GAAP free cash flow (defined as cash provided by operating activities less purchases of property, equipment and software and capitalized software development costs) increased 25.4% to $43.4 million versus $34.6 million for the first six months of 2012. The Company prepaid an additional $40.0 million of its Term Loan B in the second quarter of 2013 along with its scheduled principal payments. Its balance sheet at June 30, 2013 included $821.5 million in total bank and bond debt, net of cash and cash equivalents. Total net debt equates to leverage of approximately 3.6 times non-GAAP adjusted EBITDA for the trailing twelve-month period.
Non-GAAP Contracted Revenue
At June 30, 2013, MedAssets rolling 12-month non-GAAP contracted revenue estimate was $616.8 million (SCM segment - $378.4 million; RCM segment - $238.4 million), a year-over-year increase of 2.2%. Non-GAAP contracted revenue is the Company's estimate of contractually committed revenue to be generated under existing client contracts in the forward 12-month period.
2013 Financial Guidance Updated
MedAssets updated its full-year 2013 financial guidance ranges, as follows:
|($ in millions, except per share)||FY 2013||Y-Y % change|
|SCM segment||$416.0 - 424.0||5.7 - 7.7%|
|RCM segment||255.0 - 261.0||3.4 - 5.9|
|Total Net Revenue||673.0 - 683.0||5.1 - 6.7|
|Non-GAAP adjusted EBITDA||217.0 - 225.0||4.7 - 8.5%|
|GAAP EPS - diluted||0.38 - 0.44||nm|
|Non-GAAP adjusted EPS - diluted||$1.26 - 1.32||11.5 -16.8%|
Conference Call Information
|Time/Date:||5:00 p.m. ET today, Wednesday, July 31, 2013|
|Phone:||855-410-0553 (or 646-583-7389 for international/local callers), PIN code 816274|
http://ir.medassets.com, "Events & Presentations" page; Archive will be available for at least 30 days
|Replay:||Call 877-764-8714 or 646-583-7395 (PIN code 338589)|
Note: The live webcast will include a slide presentation, a copy of which is available on http://ir.medassets.com in the "Events & Presentations" section in conjunction with today's event.
MedAssets (NAS: MDAS) partners with healthcare providers to improve their financial strength by implementing revenue cycle, spend and clinical resource management solutions that help capture revenue, control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 4,200 hospitals and 122,000 non-acute healthcare providers. The company currently manages more than $50 billion in supply spend and touches over $365 billion in gross patient revenue annually through its revenue cycle solutions. For more information, go to www.medassets.com.
Use of Non-GAAP Financial Information
In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management and the board of directors in their financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with the following non-GAAP financial information: gross fees; gross administrative fees; revenue share obligation; EBITDA; adjusted EBITDA; adjusted EBITDA margin; adjusted net income; diluted adjusted EPS; free cash flow; and contracted revenue. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, where possible, are included in the accompanying financial schedules. Also, see "Use of Non-GAAP Financial Measures" following the financial schedules for more information.
Safe Harbor Statement
This Press Release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, and include the intent, belief or current expectations of the Company and its management team with respect to the Company's future business operations that include, but are not limited to: 2013 financial guidance, revenue growth and other financial projections and forecasts; and the Company's ability to successfully integrate and capitalize on synergies associated with acquisitions. Any forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those contemplated by the forward-looking statements in this Press Release include, but are not limited to: failure to realize improvements in performance, efficiency and profitability; failure to complete anticipated sales under negotiations; failure to successfully implement revenue backlog; lack of revenue growth; customer losses; and adverse developments with respect to the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can also be found in the Company's Risk Factor disclosures in its Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission and available at http://ir.medassets.com . The Company disclaims any responsibility to update any forward-looking statements.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|In 000s, except per share data||Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|2013||2012||% Change||2013||2012||% Change|
|Administrative fees, net||$||70,502||$||66,695||5.7%||$||147,021||$||132,111||11.3%|
|Other service fees||100,240||96,315||4.1%||196,558||180,789||8.7%|
|Total net revenue||170,742||163,010||4.7%||343,579||312,900||9.8%|
|Cost of revenue (inclusive of certain amortization expense)||37,496||34,730||8.0%||71,764||66,013||8.7%|
|Product development expenses||7,975||6,638||20.1%||16,476||13,560||21.5%|
|Selling and marketing expenses||20,285||19,178||5.8%||34,027||33,726||0.9%|
|General and administrative expenses||57,199||56,574||1.1%||115,819||110,410||4.9%|
|Acquisition and integration-related expenses||1,435||2,028||-29.2%||9,465||3,277||188.8%|
|Amortization of intangibles||16,115||18,481||-12.8%||32,616||37,411||-12.8%|
|Total operating expenses||150,381||144,910||3.8%||299,220||278,092||7.6%|
|Other income (expense):|
|Income before income taxes||8,256||1,457||466.6%||20,946||1,093||1816.4%|
|Income tax expense (benefit)||3,172||(794)||nm||8,158||(919)||nm|
|Basic net income per share||0.09||0.04||125.0%||0.22||0.04||450.0%|
|Diluted net income per share||$||0.08||$||0.04||100.0%||$||0.21||$||0.03||600.0%|
|Weighted average shares — basic||59,387||57,174||59,198||57,102|
|Weighted average shares — diluted||60,665||58,678||3.4%||60,628||58,637||3.4%|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||December 31,|
|In 000s, except share and per share amounts||2013||2012|
|Cash and cash equivalents||$||716||$||13,734|
Accounts receivable, net of allowances of $2,458 and $3,046 as of June 30, 2013 and December 31, 2012, respectively
|Deferred tax asset, current||5,113||11,126|
|Prepaid expenses and other current assets||21,545||21,791|
|Total current assets||122,943||142,997|
|Property and equipment, net||151,994||134,361|
|Other long term assets|
|Intangible assets, net||297,547||330,163|
|Other long term assets||1,367,020||1,400,879|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued revenue share obligation and rebates||78,087||74,274|
|Accrued payroll and benefits||29,819||40,085|
|Other accrued expenses||15,427||14,145|
|Current portion of deferred revenue||52,292||55,756|
|Current portion of notes payable||15,500||15,500|
|Current portion of finance obligation||244||233|